1. Home
  2. PAYS vs DSGN Comparison

PAYS vs DSGN Comparison

Compare PAYS & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Paysign Inc.

PAYS

Paysign Inc.

HOLD

Current Price

$12.91

Market Cap

780.3M

ML Signal

HOLD

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

HOLD

Current Price

$15.24

Market Cap

853.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PAYS
DSGN
Founded
2001
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
780.3M
853.8M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
PAYS
DSGN
Price
$12.91
$15.24
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
4
Target Price
$9.42
$15.25
AVG Volume (30 Days)
814.8K
522.8K
Earning Date
05-12-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
85.71
N/A
EPS
0.20
N/A
Revenue
$24,120,434.00
N/A
Revenue This Year
$33.83
N/A
Revenue Next Year
$14.89
N/A
P/E Ratio
$62.65
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.08
$5.28
52 Week High
$14.43
$17.25

Technical Indicators

Market Signals
Indicator
PAYS
DSGN
Relative Strength Index (RSI) 58.76 57.48
Support Level $4.95 $9.78
Resistance Level $14.43 $15.99
Average True Range (ATR) 0.68 0.64
MACD -0.27 -0.06
Stochastic Oscillator 32.13 50.55

Price Performance

Historical Comparison
PAYS
DSGN

About PAYS Paysign Inc.

PaySign Inc is a provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers, and government institutions. The company creates customized payment solutions for clients across industries, including pharmaceutical, healthcare, hospitality, and retail. The The company generates revenues from pharma card programs through card program management fees, transaction claim processing fees, interchange fees, customer service fees, other billable service fees and settlement income and other revenues are generated through cardholder fees, interchange fees, program management fees, load fees and breakage.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.

Share on Social Networks: